SAB BIO Forms Clinical Advisory Board for SAB-142 Type 1 Diabetes Development

SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical firm headquartered in Miami, has announced the creation of a clinical advisory board to guide the development of their leading therapeutic candidate, SAB-142. The company's innovative platform focuses on providing human anti-thymocyte immunoglobulin (hIgG) to potentially delay or prevent the progression of type 1 diabetes (T1D). 

The newly formed board includes global experts with extensive experience in T1D therapy development. Their role is to offer strategic direction, provide insights on clinical protocols, and contribute to research initiatives as SAB advances its work in disease-modifying therapies for T1D.

Samuel J. Reich, Chairman and CEO of SAB, expressed appreciation for the collaboration with these esteemed professionals. He highlighted the potential of SAB-142 to transform T1D management by offering a safe and reliable treatment option that could delay the clinical onset and progression of the disease. Reich emphasized the importance of the advisory board's contributions as SAB-142 moves through the clinical development process.

The founding members of the SAB clinical advisory board include:

- Colin Mark Dayan, MA, MBBS, FRCP, PhD, Professor of Clinical Diabetes and Metabolism at Cardiff University School of Medicine.
- Michael Haller, MD, Professor and Chief Silverstein Family Eminent Scholar at the University of Florida.
- Stephen Gitelman, MD, Professor of Pediatrics at the University of California, San Francisco.
- Thomas Kay, MBBS, PhD, Professor of Medicine at the University of Melbourne.
- Chantal Mathieu, MD, PhD, Professor of Medicine at Katholieke Universiteit Leuven.
- Jay S. Skyler, MD, MACP, FRCP, Professor of Medicine, Pediatrics, & Psychology, at the University of Miami Leonard M. Miller School of Medicine.
- John Wentworth MBBS, FRACP, Professor of Medicine at Royal Melbourne Hospital.

SAB-142 is designed as a human alternative to rabbit anti-thymocyte globulin (ATG), which has shown efficacy in slowing T1D progression in various clinical trials. Rabbit ATG works by modulating the immune response to prevent destruction of insulin-producing beta cells in the pancreas, critical for regulating blood sugar levels. However, rabbit ATG often induces serum sickness and anti-drug antibodies in patients due to its animal origin.

In contrast, SAB-142 is a human antibody intended to provide safe, consistent re-dosing, avoiding the significant adverse immune reactions associated with animal-derived ATG. This characteristic makes SAB-142 a promising candidate for lifelong treatment of T1D, a chronic condition requiring ongoing management.

SAB Biotherapeutics specializes in developing human, multi-targeted, high-potency immunoglobulins (IgGs) without relying on human donors or convalescent plasma. Their lead asset, SAB-142, employs a disease-modifying approach aimed at delaying the onset and potentially preventing the progression of T1D. Through advanced genetic engineering, SAB has developed Transchromosomic (Tc) Bovine™, the only transgenic animal with a human artificial chromosome. This allows their DiversitAb™ drug development system to produce a diverse range of high-potency human IgGs tailored to address numerous unmet needs in human diseases.

SAB's innovative platform and the strategic insights from their newly formed clinical advisory board position them at the forefront of T1D research, with the potential to significantly impact disease management and patient outcomes.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!